TY - JOUR
T1 - Disialylated apolipoprotein C-III proteoform is associated with improved lipids in prediabetes and type 2 diabetes1
AU - Koska, Juraj
AU - Yassine, Hussein
AU - Trenchevska, Olgica
AU - Sinar, Shripad
AU - Schwenke, Dawn C.
AU - Yen, Frances T.
AU - Billheimer, Dean
AU - Nelson, Randall W.
AU - Nedelkov, Dobrin
AU - Reaven, Peter D.
N1 - Funding Information:
This work was supported by the National Institutes of Health Grants R24- DK090958 (R.W.N./P.D.R.), R01-067690 (P.D.R.), R01-HL94775 (P.D.R.), R01-DK082542 (R.W.N.), and K23-HL107389 and 15BGIA25690024 from the American Heart Association (H.Y.), the Cooperative Studies Program of the Department of Veterans Affairs Office of Research and Development (#431), and Takeda Pharmaceuticals. The contents of this article do not represent the views of the Department of Veterans Affairs or the United States Government. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
PY - 2016/5
Y1 - 2016/5
N2 - The apoC-III proteoform containing two sialic acid residues (apoC-III2) has different in vitro effects on lipid metabolism compared with asialylated (apoC-III0) or the most abundant monosialylated (apoC-III1) proteoforms. Cross-sectional and longitudinal associations between plasma apoC-III proteoforms (by mass spectrometric immunoassay) and plasma lipids were tested in two randomized clinical trials: ACT NOW, a study of pioglitazone in subjects with impaired glucose tolerance (n = 531), and RACED (n = 296), a study of intensive glycemic control and atherosclerosis in type 2 diabetes patients. At baseline, higher relative apoC-III2 and apoC-III2/apoC-III1 ratios were associated with lower triglycerides and total cholesterol in both cohorts, and with lower small dense LDL in the RACED. Longitudinally, changes in apoC-III2/apoC-III1 were inversely associated with changes in triglycerides in both cohorts, and with total and small dense LDL in the RACED. apoC-III2/apoC-III1 was also higher in patients treated with PPAR-γ agonists and was associated with reduced cardiovascular events in the RACED control group. Ex vivo studies of apoC-III complexes with higher apoC-III2/ apoC-III1showed attenuated inhibition of VLDL uptake by HepG2 cells and LPL-mediated lipolysis, providing possible functional explanations for the inverse association between a higher apoC-III2/apoC-III1 and hypertriglyceridemia, proatherogenic plasma lipid profiles, and cardiovascular risk.- Koska, J., H. Yassine, O. Trenchevska, S. Sinari, D. C. Schwenke, F. T. Yen, D. Billheimer, R. W. Nelson, D. Nedelkov, and P. D. Reaven. Disialylated apolipoprotein C-III proteoform is associated with improved lipids in prediabetes and type 2 diabetes. J. Lipid Res. 2016. 57: 894-905.
AB - The apoC-III proteoform containing two sialic acid residues (apoC-III2) has different in vitro effects on lipid metabolism compared with asialylated (apoC-III0) or the most abundant monosialylated (apoC-III1) proteoforms. Cross-sectional and longitudinal associations between plasma apoC-III proteoforms (by mass spectrometric immunoassay) and plasma lipids were tested in two randomized clinical trials: ACT NOW, a study of pioglitazone in subjects with impaired glucose tolerance (n = 531), and RACED (n = 296), a study of intensive glycemic control and atherosclerosis in type 2 diabetes patients. At baseline, higher relative apoC-III2 and apoC-III2/apoC-III1 ratios were associated with lower triglycerides and total cholesterol in both cohorts, and with lower small dense LDL in the RACED. Longitudinally, changes in apoC-III2/apoC-III1 were inversely associated with changes in triglycerides in both cohorts, and with total and small dense LDL in the RACED. apoC-III2/apoC-III1 was also higher in patients treated with PPAR-γ agonists and was associated with reduced cardiovascular events in the RACED control group. Ex vivo studies of apoC-III complexes with higher apoC-III2/ apoC-III1showed attenuated inhibition of VLDL uptake by HepG2 cells and LPL-mediated lipolysis, providing possible functional explanations for the inverse association between a higher apoC-III2/apoC-III1 and hypertriglyceridemia, proatherogenic plasma lipid profiles, and cardiovascular risk.- Koska, J., H. Yassine, O. Trenchevska, S. Sinari, D. C. Schwenke, F. T. Yen, D. Billheimer, R. W. Nelson, D. Nedelkov, and P. D. Reaven. Disialylated apolipoprotein C-III proteoform is associated with improved lipids in prediabetes and type 2 diabetes. J. Lipid Res. 2016. 57: 894-905.
KW - Lipoproteins
KW - Mass spectrometry
KW - Proteomics
KW - Triglycerides
KW - Very low density lipoprotein
UR - http://www.scopus.com/inward/record.url?scp=84971212681&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84971212681&partnerID=8YFLogxK
U2 - 10.1194/jlr.P064816
DO - 10.1194/jlr.P064816
M3 - Article
C2 - 26945091
AN - SCOPUS:84971212681
SN - 0022-2275
VL - 57
SP - 894
EP - 905
JO - Journal of Lipid Research
JF - Journal of Lipid Research
IS - 5
ER -